RxDoctor Payments Data

Haylie Wetzel, NP

Nurse Practitioner · Bismarck, NDNPI 1912684531

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,799in general payments, 2019–2025

Across 84 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$259
  • Daiichi Sankyo Inc.$240
  • Pfizer$233
  • E.r. Squibb & Sons, L.L.C.$149
  • Amgen$149
  • Actelion Pharmaceuticals US, Inc.$141
  • plus $629 from 15 others

What the payments were for

  • Food & beverage$1,799100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,799 in reported general payments places this provider in the 90th percentile of 455 nurse practitioner providers in North Dakota.

See all nurse practitioner providers in North Dakota

Medicare billing

Part B allowed, 2024
$52,437
Medicare patients
412
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$211,420
JardianceEmpagliflozin50$45,371
XareltoRivaroxaban51$35,493
EntrestoSacubitril/Valsartan34$30,597
Repatha SyringeEvolocumab11$10,643
Metoprolol Succinate425$9,238
Praluent PenAlirocumab15$9,109
Repatha SureclickEvolocumab11$5,735
Rosuvastatin Calcium321$5,728
Atorvastatin Calcium246$2,991
Bumetanide55$2,404
Ezetimibe92$2,360
Digoxin72$2,086
ClopidogrelClopidogrel Bisulfate110$1,604
Losartan Potassium163$1,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$211,420257 claims
Boehringer IngelheimJardiance$63$45,37150 claims
Johnson & JohnsonXarelto$20$35,49351 claims
NovartisEntresto$259$30,59734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 nurse practitioner providers in North Dakota.

Other nurse practitioner in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →